Enter Note Done
Go to previous page in this tab
Session
  • Special Interest Group
  • Bookmark Icon
  • SIG | Neuropharmacology: Use of Anti-seizure Medications in the Era of AI and Precision Medicine
    • Schedule
    Notes
  • Set Timezone

Overview
There have been several new anti-seizure medications (ASM) FDA-approved for treatment of epilepsy in the last 5-6 years (for example: Stiripentol, Fenfluramine, Ganaxolone, Cenobamate). These medications have new mechanisms of action, novel drug-drug interactions, and unique side effects. The 2025 Neuropharmacology SIG addresses the mechanisms of action of these new medications, use of EMR-integrated AI to guide the use of ASMs in different clinical scenarios, detection of drug-drug interactions, and use of ASMs in epilepsy treatment from a precision medicine approach. Following the presentations, a moderated panel discussion addresses questions from the audience.
Learning Objectives
Following participation in this activity, participants will be able to:
  • Identify mechanisms of action and clinical indications of newly FDA-approved anti-seizure medications
  • Understand advantages and challenges of AI models for identifying drug-drug interactions in epilepsy, enhancing patient safety and treatment efficacy
  • Describe use of anti-seizure medications from a precision medicine perspective
Chairs
Rachel Kinn, PharmD, BCPPS; and Cristina Trandafir, MD, PhD
Program
Introduction | Rachel Kinn, PharmD, BCPPS
Voltage Shift: Decoding the Mechanisms Powering New Anti-seizure Medications | Heather Nichols, BCCPS, PharmD
AI's Impact on Neuropharmacology in Epilepsy – Advantages and Challenges in Clinical Utilization | Archana Pasupuleti, MD, MBA
Friend or Foe? Use of Anti-seizure Medications in the Era of Precision Medicine | Cristina Trandafir, MD, PhD

Types
Career Stage
Target Audience
Categories